ArticlePloS one2025
The impact of brain-derived neurotrophic factor gene polymorphisms on post-stroke naming in aphasia.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Post-stroke aphasia, or language deficits after stroke, afflicts 20-30% of survivors and often persists into the chronic phase. The protein brain-derived neurotrophic factor has been identified as important for neuroplasticity, and is regulated by the brain-derived neurotrophic factor gene. A patient's brain-derived neurotrophic factor genotype may influence their post-stroke aphasia recovery. This study aimed to investigate the impact of a single nucleotide polymorphism in the brain-derived neurotrophic factor gene, rs6265, on language recovery. We hypothesized that individuals with the most common polymorphism would exhibit better chronic naming performance and a more favorable recovery trajectory from poor acute performance to strong chronic outcomes compared to those without the polymorphism. We retrospectively analyzed data from 77 participants with post-stroke aphasia from three recent or ongoing studies that included both repeated standardized picture naming assessments in the acute, subacute, and chronic phases and brain-derived neurotrophic factor genotyping. Statistical analyses controlled for acute performance and lesion volume when evaluating the effect of brain-derived neurotrophic factor genotype on the probability of better chronic language recovery (Aim 1) and on the probability of a person with poor acute performance later having strong performance in the subacute to chronic period (Aim 2). Results indicated that those with the most common polymorphism had a 33% higher likelihood of high naming scores in the chronic phase compared to those with the with less common polymorphisms (with a methionine allele). Individuals with the typical polymorphism whose acute naming was below average after stroke exhibited a 24% higher likelihood of recovering to be above average. Brain-derived neurotrophic factor status was not a significant independent predictor of outcome in either model. Our results suggest that the effect of brain-derived neurotrophic factor polymorphisms on chronic post-stroke aphasia recovery is, at best, modest and underscores the importance of individualized approaches to neurorehabilitation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.